All In Biotech

Drug Trial Radar · NCT01804686

A Long-term Extension Study of PCI-32765 (Ibrutinib)

PCI-32765CAN3001: A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

539

Actual

Start

Sep 9, 2013

Primary completion

Dec 31, 2026

Study completion Dec 31, 2029

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
Collaborators
Pharmacyclics LLC.
First posted
Mar 5, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively receiving treatment with ibrutinib, and who continue to benefit from ibrutinib treatment.

Conditions

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Mantle Cell Lymphoma
  • Follicular Lymphoma
  • Diffuse Large B-cell Lymphoma
  • Waldenstrom Macroglobulinemia
  • Chronic Graft Versus Host Disease

Interventions

  • IbrutinibDrug

    Ibrutinib will be given orally as capsules, once daily continuously, according to the current dosing regimen established in the parent ibrutinib clinical study (560 mg, 420 mg, 280 mg, or 140 mg), at approximately the same time each day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants affected by an adverse eventTime frame: Up to 30 days after the last dose of study drug, or until the start of a subsequent systemic anti-cancer therapy, if earlier

Locations

156 sites in 29 countries. Site status is shown where the registry gives one.

  • Site not named

    Duarte, California

  • Site not named

    La Jolla, California

  • Site not named

    Los Angeles, California

  • Site not named

    Orange, California

  • Site not named

    Stanford, California

  • Site not named

    Norwalk, Connecticut

  • Site not named

    Marietta, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Goshen, Indiana

  • Site not named

    Westwood, Kansas

  • Site not named

    Louisville, Kentucky

  • Site not named

    Boston, Massachusetts

  • Site not named

    Ann Arbor, Michigan

  • Site not named

    Battle Creek, Michigan

  • Site not named

    Detroit, Michigan

  • Site not named

    St Louis, Missouri

  • Site not named

    Lebanon, New Hampshire

  • Site not named

    Hackensack, New Jersey

  • Site not named

    New York, New York

  • Site not named

    Goldsboro, North Carolina

  • Site not named

    Columbus, Ohio

  • Site not named

    Eugene, Oregon

  • Site not named

    Portland, Oregon

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Sioux Falls, South Dakota

  • Site not named

    Houston, Texas

  • Site not named

    Charlottesville, Virginia

  • Site not named

    Seattle, Washington

  • Site not named

    Morgantown, West Virginia

  • Site not named

    Madison, Wisconsin

  • Site not named

    Ciudad Autonoma Buenos Aires, Argentina

  • Site not named

    Ciudad de Buenos Aires, Argentina

  • Site not named

    Adelaide, Australia

  • Site not named

    Coburg, Australia

  • Site not named

    Concord, Australia

  • Site not named

    Heidelberg, Australia

  • Site not named

    Melbourne, Australia

  • Site not named

    Perth, Australia

  • Site not named

    Prahran, Australia

  • Site not named

    Wahroonga, Australia

Showing 40 of 156 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.